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The impact of human leukocyte antigen (HLA) donor-speciﬁc antibodies (DSA) on cord blood (CB) engraft-
ment is controversial. We evaluated the inﬂuence of pre-existing HLA-antibodies (HLA-Abs) on engraftment
in 82 double-unit CB recipients (median age, 48 years) who underwent transplantation for hematologic
malignancies. Of 28 patients (34%) with HLA-Abs, 12 had DSA (median mean ﬂuorescence intensity 5255;
range, 1057 to 9453). DSA patients had acute leukemia (n ¼ 11) or myelodysplasia (n ¼ 1) and all received
either high-dose or reduced-intensity (but myeloablative) conditioning. After myeloablative CB trans-
plantation (CBT) (n ¼ 67), sustained donor engraftment was observed in 95% without HLA-Abs (median, 23
days), 100% with nonspeciﬁc HLA-Abs (median, 23 days), and 92% with DSA (median, 31 days, P ¼ .48). Of 6
patients with HLA-Abs to 1 unit, 3 engrafted with that unit and 3 with the other. Of 6 patients with HLA-Abs
against both units, 1 had graft failure despite being 100% donor, and 5 engrafted with 1 unit. Successful donor
engraftment is possible in patients with DSA after myeloablative double-unit CBT. Our data suggest potential
deleterious effects of DSA can be abrogated in patients with hematologic malignancies.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION graft failure in single-unit CBT [12,13]. However, double-unit
Hematopoietic stem cell (HSC) allograft recipients are
often allo-immunized. This sensitization may include anti-
bodies (Abs) directed against mismatched HLA of potential
donors. Animal models suggest that such Abs may be a
barrier to allogeneic engraftment [1,2]. Moreover, graft fail-
ure is observed in approximately 5% of unrelated allograft
recipients [3], and analyses have suggested this may relate, at
least in part, to pre-existing donor-speciﬁc Abs (DSA) [4-7].
In cord blood (CB) transplantation (CBT), marked donor-
recipient HLA disparity and low cell dose are additional
risk factors for graft failure. The 20% graft failure rates after
single-unit CBT [8,9] have been reduced by new conditioning
and immunosuppression and by the introduction of double-
unit CBT [10,11]. Nonetheless, graft failure has not been
eliminated and DSA is an accepted additional risk factor fordgments on page 738.
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14.01.017CBT studies have yielded conﬂicting results [14-16]. Although
some investigators have recommended avoiding units ag-
ainst which the recipient has DSA [12-14,16,17], this practice
is controversial. We, therefore, analyzed the inﬂuence of
HLA-Ab on the likelihood of engraftment and unit domi-
nance in 82 double-unit CBT recipients. Our hypothesis was
that the combination of immunosuppressive conditioning,
lack of antithymocyte globulin (ATG), and double-unit grafts
in patients with hematologic malignancies may abrogate the
adverse effects of DSA upon engraftment described in CBT
recipients in the literature.METHODS
Patient and Graft Characteristics
Consecutive ﬁrst allograft recipients who underwent transplantation
with double-unit CB grafts for the treatment of hematologic malignancies
consenting to pretransplantation HLA-Abs analysis were analyzed. Patients
and/or guardians also provided informed consent to transplantation and
outcome analysis. Patients underwent transplantation during the period
from July 2008 to July 2012. Patients received high-dose conditioning (n ¼
21), reduced-intensity but functionally myeloablative conditioning (n ¼ 46,
predominantly with cyclophosphamide [Cy] 50mg/kg, ﬂudarabine [Flu] 150
mg/m2, thiotepa [Thio] 10 mg/kg, and total body irradiation [TBI] 400 cGy11
[Cy 50/Flu 150/Thio 10/TBI 400]), or nonmyeloablative conditioning (n¼ 15).
Table 1
Patient and Graft Characteristics According to Presence of HLA Antibodies
Characteristics Total No Antibody Antibody P Value
No. of patients 82 54 (66%) 28 (34%)
Age, median (range), yr 48 (2-69) 48 (2-69) 49 (10-64) .53
Weight, median (range), kg 70 (15-125) 76 (15-125) 67 (37-93) .09
Gender, female, n (%) 34 (41%) 14 (26%) 20 (71%) <.01
Diagnosis, n (%)
AML 33 (40%) 17 (31%) 16 (57%) .06
ALL 14 (17%) 9 (17%) 5 (18%)
MDS & MPD 9 (11%) 6 (11%) 3 (11%)
Lymphoma & CLL 26 (32%) 22 (41%) 4 (14%)
Recipient CMVþ 47 (57%) 26 (48%) 21 (78%) .03
Conditioning, n (%)
High-dose myeloablative 21 (26%) 12 (22%) 9 (32%) .16
Reduced intensity* 46 (56%) 29 (54%) 17 (61%)
Nonmyeloablative 15 (18%) 13 (24%) 2 (7%)
Number of units 164 108 56
Unit-recipient HLA-A, -B antigen, -DRB1 allele match
6/6 7 (4%) 4 (4%) 3 (5%) .12
5/6 78 (48%) 45 (42%) 33 (59%)
4/6 79 (48%) 59 (55%) 20 (36%)
Inf. TNC x 107/kg
Larger 2.9 (1.5-5.6) 2.9 (1.5-5.6) 2.9 (1.5-5.5) .73
Smaller 2.0 (1.1-4.5) 2.0 (1.4-4.5) 2.0 (1.1-2.8) .46
Inf. CD34þ cell x 105/kg
Larger 1.4 (.3-4.5) 1.5 (.3-4.5) 1.3 (.4-3.0) .22
Smaller .7 (.2-1.6) .7 (.2-1.6) .6 (.2-1.5) .43
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; CLL, chronic
lymphocytic leukemia; CMV, cytomegalovirus; Inf, infused; TNC, total nucleated cells.
* Reduced-intensity conditioning was predominantly Cy 50/Flu 150/Thio 10/ TBI 400 in 44 of 46 patients. This regimen is functionally myeloablative.
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mofetil, and no patient received ATG. All patients received post-trans-
plantation granulocyte colony-stimulating factor.
CB units were selected based on 4/6 to 6/6 HLA-A, -B antigen, -DRB1
allele match to the recipient, cryopreserved total nucleated cell (TNC) dose
1.5 x 107/kg/unit (increased to 2.0 in 2011) [18], and CB bank. Above the TNC
dose threshold, HLA match was given priority. Patients and CB units were
also typed at HLA-A, -B, -C and -DQ alleles, but high-resolution match grade
at 10 alleles was not used in unit selection during this period. Patients and
units were not typed for HLA-DP. Additionally, HLA-Abs screening results
were not available at the time of unit selection and were, therefore, not
considered in selecting the graft.
HLA-Abs Screening
HLA-Abs screening was performed using LABScreen Mixed beads (One
Lambda Inc, Canoga Park, CA) that detect Class I/II Abs with a panel coated
with puriﬁed HLA antigens according to manufacturer’s instructions. Test
serum (20 mL) and controls were incubated with LABScreen beads (5 ml) in
the dark at room temperature for 30 minutes. After 3 washes, R-Phycoery-
thrineconjugated goat antihuman IgG was added, followed by incubation
and wash. Data acquisition and analysis were performed using Luminex 100
(Luminex Corporation, Austin, TX). Sample reactivity was corrected for
nonspeciﬁc binding (One Lambda’s HLA Fusion software). Positive samples
were further tested using LABScreen Single Antigen Class I/II beads. Posi-
tivity was deﬁned as adjustedmean ﬂuorescence intensity (MFI) 1000 and
derived per laboratory validations [19-21] and external proﬁciency pro-
grams. HLA-Abs proﬁles were compared with mismatched CB HLA-antigens
to identify DSA.
Assessment of Donor Engraftment and Statistical Analyses
Donor chimerism was determined serially on marrow and blood after
transplantation as previously described [10]. Sustained engraftment was
deﬁned as sustained donor-derived neutrophil recovery with total donor
chimerism  90%. The dominant unit was the only 1 detected or the unit
contributing > 50% total chimerism in serial testing. Neutrophil recovery
was the ﬁrst of 3 consecutive days with a count  .5 x 109/L.
Patient and graft characteristics were compared according to HLA-Abs
presence using a Wilcoxon rank-sum test for continuous variables and
Fisher exact test for categorical variables. Cumulative incidence functions
estimated engraftment incidence according to HLA-Abs and Gray’s test was
used to compare engraftment incidence. All tests were considered statisti-
cally signiﬁcant based on a 2-sided test at alpha level .05. All analyses were
done using R statistical software, version 2.13.2 (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
Patient and Graft Demographics According to HLA-Abs
Twenty-eight patients (34%) had pre-existing HLA-Ab.
HLA-Ab patients were predominantly female andmore likely
to be cytomegalovirus (CMV) sero-positive (Table 1). Other-
wise, there were no differences. Of the 28 patients with HLA-
Abs, 26 received myeloablative conditioning (9 high-dose
and 17 Cy 50/Flu 150/Thio 10/TBI 400 [11]), and 2 received
nonmyeloablative conditioning.
HLA-Abs were donor-speciﬁc in 12 patients. These pa-
tients were a median age of 51 years (range, 24 to 64) and a
median weight of 67 kilograms (range, 51 to 93); 10 were
female; 11 had acute leukemia and 1 had myelodysplasia;
and all received myeloablative conditioning that was of
high dose (Cy 120 mg/kg, Flu 75 mg/m2, and TBI 1375 cGy
[n ¼ 2]) or of reduced intensity but functionally myeloa-
blative (Cy 50/Flu 150/Thio 10/TBI 400 [11] [n ¼ 10]). DSA
patients received a median infused TNC dose (x 107/kg) of
2.4 (larger unit, range 1.5 to 3.4) and 2.0 (smaller unit,
range 1.4 to 2.5).Nature of HLA-Abs
The nature of HLA-Abs are summarized in Table 2. Fifteen
patients (54%) had class I Abs, 2 (7%) had class II Abs, and 11
(39%) had both. Eight patients had HLA-Abs to 1 locus only (4
HLA-A, 3 HLA-B,1 HLA-DRB1), and the remaining 20 patients
had Abs to combinations of HLA-A, -B, -C, and/or -DRB1, -DQ.
Overall, 22 patients had HLA-A Abs, 18 had HLA-B Abs, 8
had HLA-C Abs, 10 had HLA-DRB1 Abs, and 8 had HLA-DQ
Abs. Additionally, 7 patients also had Abs against HLA-DP,
but the potential contribution to engraftment outcome of
such Abs was not analyzed, as patients and CB units were not
typed for DP.
Sixteen patients had Abs without speciﬁcity for either
unit of the graft, and 12 had DSA ([median,1.5/patient; range,
1 to 4], 6 against 1 unit and 6 against both). The median MFI
Table 2
Nature of HLA Antibodies (n ¼ 28 patients)
Characteristic N (%)
HLA Speciﬁcity:
Class I Ab 15 (54%)
Class II Ab 2 (7%)
Both Class I & II 11 (39%)
Donor Speciﬁcity:
Ab: not speciﬁc for graft 16 (57%)
Donor-speciﬁc Ab (DSA) 12 (43%)
DSA speciﬁc for 1 unit 6
DSA speciﬁc for both units 6
MFI, median (range)
All Ab (n ¼ 28) 4510 (1003-18,479)
DSA (n ¼ 12) 5255 (1057-9453)
Ab indicates antibody; DSA, donor-speciﬁc Ab; MFI, mean ﬂuorescence
intensity.
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was 5255.Engraftment According to the Presence of HLA Abs
Overall, the cumulative incidence of engraftment for
myeloablative CBT recipients (n ¼ 67) was 95% (95% conﬁ-
dence interval, 87% to 98%) at 42 days after CBT. In thosewith
DSA, sustained engraftment was observed in 11 of 12 pa-
tients for a cumulative incidence of 92% with neutrophil re-
covery occurring at a median of 31 days (range, 13 to 40)
(Figure 1). The engraftment in DSA patients was not signiﬁ-
cantly different from that of patients without HLA-Abs (95%
incidence at a median of 23 days; range, 12 to 38) and pa-
tients with nonspeciﬁc HLA-Abs (100% incidence at a median
of 23 days; range, 12 to 37) (Figure 1), P ¼ .48 by Gray’s test.
When patients with DSA (n ¼ 12) and those without DSA
(n ¼ 55) were compared, there was also no difference in the
overall speed and success of engraftment (P ¼ .25).
One unit predominated in engraftment after myeloa-
blative conditioning in all patients. Of the 6 DSA patients
with HLA-Abs to only 1 unit of the graft, 3 engrafted with
that unit and 3 with the other. Of 6 patients with HLA-Abs0 10 20 30 40
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Figure 1. Cumulative incidence of sustained donor engraftment according
to the presence of HLA-Abs after myeloablative conditioning (n ¼ 67). The
presence of pre-existing HLA-Abs (nonspeciﬁc or donor-speciﬁc) did not in-
ﬂuence the cumulative incidence of sustained donor neutrophil engraftment.against both units, 1 had graft failure despite being 100%
donor with 1 unit in the day-21 bonemarrow and died in the
setting of early onset multiorgan failure, and 5 engrafted
with 1 unit. There were no differences in total donor
chimerism, according to the presence of nonspeciﬁc Abs or
DSA with each of the patient groups (no HLA-Abs, nonspe-
ciﬁc Abs, and DSA) having a median total donor chimerism of
100% from 21 days after CBT.
As the infused viable CD34þ cell dose of the dominant
unit is a critical determinant of engraftment after double-
unit CBT [22,23], the cell doses in patients with and
without DSA were compared. The mean dominant unit
infused viable CD34þ cell dose in engrafting DSA patients
was lower at .74 x 105/kg (range, .2 to 1.61) than that of the 53
without Abs or with nonspeciﬁc Abs (1.22 x 105/kg; range, .2
to 4.08; P ¼ .02).
Of the recipients of nonmyeloablative conditioning (n ¼
15), 14 engrafted. However, lack of DSA precluded their
evaluation in nonmyeloablative CBT recipients.
DISCUSSION
Multiple reports have suggested an adverse effect of DSA
upon engraftment after CBT. However, in this study we
observed a high incidence of sustained engraftment in DSA
patients with 11 of 12 patients engrafting. We hypothesize
that this is attributed to the nature of the conditioning and/or
immune suppression delivered to DSA patients in combina-
tion with double-unit grafts [10,11], although the exact
contributions of each of these components cannot be dis-
cerned individually. Although 10 of 12 DSA patients were not
appropriate for high-dose myeloablation, they were treated
with a reduced-intensity but functionally myeloablative and
highly immunosuppressive regimen of Cy 50/Flu 150/Thio
10/TBI 400 [11], supplemented with double-unit grafts.
Although no conclusion can be made about recipients of
nonmyeloablative conditioning, our ﬁndings suggest that
when combined with a double-unit graft, intensiﬁed sup-
pression of the recipient’s ability to reject the graft with Cy
50/Flu 150/Thio 10/TBI 400 may be able to abrogate any
potential deleterious effects of donor-speciﬁc HLA-Abs. It is
also possible that omission of ATG could facilitate engraft-
ment in this setting given that a T-replete CB graft may be
better able to overcome negative recipient immunologic
factors, such as HLA-Ab.
Interpretation of the single case of graft failure in the CBT
recipient with DSA is confounded by this patient’s early-
onset multiorgan failure that could have contributed to
poor graft function despite being 100% donor. In addition,
although there was no difference in the overall engraftment
according to DSA, it was notable that the median time
to recovery in DSA patients was 31 days. By chance, however,
these patients had a signiﬁcantly lower infused viable CD34þ
cell dose in their dominant units. Dominant unit infused
viable CD34þ cell dose is a critical determinant of engraft-
ment speed in double-unit CBT recipients [22,23]. Thus,
although a contribution of DSA to delayed engraftment
cannot be excluded, the lower infused viable CD34þ cell dose
could explain this observation. This is an important question,
as the speed of neutrophil engraftment is a critical determi-
nant of transplantation-related mortality after double-unit
CBT as shown in University of Minnesota/Fred Hutchinson
Cancer Research Center [24] and unpublished Memorial
Sloan Kettering Cancer Center (J. Barker, 2013) analyses.
Multivariate analysis of large numbers of patients controlling
for the infused cell dose of the engrafting unit is the only
P.B. Dahi et al. / Biol Blood Marrow Transplant 20 (2014) 735e747738method by which a potential further additional contribution
of DSA to slowing engraftment could be further investigated.
Furthermore, in our study, there was no indication that DSA
inﬂuenced unit dominance. Unit dominance is likely related
to CB hematopoietic potential [25] and immune-mediated
graft-versus-graft reactions [10,22,26-28].
Our report adds to the controversy concerning the rele-
vance of HLA-Abs in CBT in patients with hematologic ma-
lignancies. Notably, our ﬁndings are consistent with the
Brunstein double-unit CBT study (n ¼ 126) that reported a
comparable cumulative incidence of engraftment in DSA and
non-DSA patients and no association with unit dominance
[15]. However, our ﬁndings differ from the Cutler study [14].
These investigators found a negative effect of DSA on double-
unit CB engraftment in 73 patients (most of whom received
ATG). Our results are also in contrast to the registry report of
Ruggeri et al., who observed a 44% incidence of engraftment
in 14 patients with DSAwho underwent transplantation after
reduced-intensity conditioning [16]. Of note, although the
median DSAMFI in the Ruggeri study (3900) and ours (5255)
were similar, there are important differences between the
patients in that report and the Memorial Sloan Kettering
Cancer Center experience. For example, of the 14 patients
with DSA in the Ruggeri series, 4 had bone marrow failure
syndromes, 7 received single-unit grafts, and 8 received a
200 cGy TBI-based preparative regimen that is of low in-
tensity and has been associated with graft rejection in the
absence of recent prior combination chemotherapy [29].
In addition to differences in patient populations, unit selec-
tion, conditioning, immunosuppression, and ATG inclusion,
conﬂicting results may also be explained by variations in
HLA-Ab assays. Assays could vary in sensitivity and/or what
threshold constitutes a positive test.
Overall, our data suggest that the negative effect of HLA-
Abs described in CBT literature can be abrogated with
appropriate conditioning, immunosuppression, and double-
unit grafts. However, there are many unanswered ques-
tions. For example, no statement can be made about the
ability to engraft patients with DSA undergoing double-unit
CBT after nonmyeloablative conditioning. Additionally, even
if adverse effects of low- and intermediate-intensity DSA can
be abrogated, it is not known if the same would be true for
high-intensity DSA. Clearly, further investigation is war-
ranted to determine when HLA-Abs may be prohibitive and
how they can be overcome. A further question is how our
ﬁndings should inﬂuence clinical practice. Incorporation of
HLA-Ab testing into unit selection algorithms for double-unit
CBT in patients with hematologic malignancies could dictate
the selection of less desirable, lower dosed, and/or lesser
HLA-matched units, which could increase the risk of
transplantation-related mortality [30]. If multiple compara-
ble units are available, it is reasonable to avoid those against
which the recipient has antibodies, especially if the MFI is
very high. However, if the choice of units is limited, our data
suggest that engraftment after double-unit CBT is possible
with the conditioning regimens described in this report in
patients with hematologic malignancies.
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Although hypereosinophilia (HE) associated with chronic graft-versus-host disease (GVHD) has long been
recognized, biological data on this phenomenon are scarce. Here we compare patients with chronic GVHD
with HE together with a clonal T cell expansion and control patients with acute or chronic GVHD but without
HE. These clonal expansions share a CD8þ TC1 phenotype rather than a CD4þ Th2 proﬁle. In contrast to the
drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, these allogeneic CD8þ clones do
not recognize the epitopes of herpesviruses. Furthermore, these TC1 clones do not produce IL-17 as described
in the DRESS syndrome.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (GVHD), the leading
cause of nonrelapse mortality after allogeneic stem cell trans-
plantation, is frequently associated with hypereosinophilia
(HE). HE may precede or be present at the diagnosis of GVHD,
or may reappear with ﬂare-ups [1]. HE was speciﬁcally
mentioned in the ﬁrst published description of chronic GVHD
[2] and has been added to the nondiagnostic criteria by the
National InstitutesofHealthConsensusConferenceonChronic
GVHD [3]. Despite this, however, the biology of HE associated
with chronic GVHD has been poorly described to date [4,5]. In
this report, we describe HE occurring together with a clonal
T cell expansion of the TC1 phenotype.PATIENTS AND METHODS
Patients
We studied 6 adult patients (5 males and 1 female) with extensive
chronic GVHD-associated HE and 4 adult controls with acute or chronic
GVHD but without HE. Five patients with HE and 2 controls had undergone
transplantation with peripheral blood stem cells. The donor was an HLA-
identical sibling for 4 of the 5 patients and for both controls. All but 1 pa-
tient with HE underwent transplantation for a hematologicmalignancy after
a reduced-intensity conditioning regimen. At the onset of HE, all patients
were in hematologic remission, with 100% donor chimerism based on
quantitative PCR (qPCR) of variable number tandem repeat sequences.
GVHD characteristics are summarized in Table 1. This study was approved by
the Ethics Committee of Saint-Louis Hospital.Methods
T cell repertoire
Peripheral blood mononuclear cells were separated using a lymphocyte
separationmedium (Eurobio, Les Ulis, France), and 5-10106 cellswere stored
after lysis in TriReagent solution (Molecular Research Center, Cincinnati, OH)
at 80C. RNA was subsequently extracted following the manufacturer’s
instructions. Then 2-5 mg of total RNAwas reverse-transcribed into cDNAusing
the Superscript III ﬁrst-strand synthesis system for RT-PCR (Invitrogen,
Cergy-Pontoise, France). T cell receptor beta V qPCR ampliﬁcation, beta chain
variable and constant runoff using an internal beta chain constant ﬂuores-
cent primer, gel running, and immunoscope analysis were performed as
described previously [6].
